Key Takeaways
- VeonGen Therapeutics plans to report on the clinical progress of VG801, an investigational gene therapy for ABCA4-associated retinal disease, at the ARVO 2026 Annual Meeting
- VG801 reportedly showed encouraging preliminary efficacy and a favorable safety profile in the ongoing phase 1/2 trial
- According to the company, a novel virtual reality visual test showing functional gains has been accepted into the FDA’s Rare Disease Endpoint Advancement Pilot Program
VeonGen Therapeutics announced that an oral presentation on the clinical progress of VG801 will be delivered at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting that is being held from May 3 to 7 in Denver. VG801, an investigational gene therapy for ABCA4-associated retinal disease, including Stargardt disease, is being evaluated in an ongoing phase 1/2 first-in-human clinical trial assessing VG801’s safety, tolerability, and preliminary efficacy (NCT07002398).
Both adult and pediatric patients have been dosed. Of these, nine have completed 6-month follow-up, and some have reached 12 months. According to the company, VG801 has been well tolerated, with no dose-limiting or serious adverse events reported to date.
Per VeonGen Therapeutics, preliminary efficacy data have shown consistent functional improvements in patients’ BCVA and a newly developed virtual reality visual test (VRVT), with improvements sustained through 6- and 12-month follow-up. The company stated that VRVT has been accepted into the FDA Rare Disease Endpoint Advancement Pilot Program, supporting the development of VRVT as a novel functional vision endpoint. The company said it has conducted a dedicated VRVT validation study to support its potential use in a future pivotal trial toward a Biologics License Application submission.
Clinical data from the ongoing study will be reported in an oral presentation at the ARVO 2026 Annual Meeting during the “Stem Cell and Gene Therapy” session.
According to the company, VG801 has received key regulatory authorizations, including FDA Investigational New Drug clearance, European Medicines Agency Clinical Trial Application approval, and China Center for Drug Evaluation Investigational New Drug approval, and it has been granted FDA Regenerative Medicine Advanced Therapy designation, supporting enhanced regulatory interactions and a potential accelerated development pathway.
“Our focus remains on efficiently advancing clinical programs to bring novel therapies to patients with high unmet medical needs, while exploring strategic partnerships to leverage VG801 and our proprietary technology platforms across ophthalmology and other therapeutic areas,” said Dr. Caroline Man Xu, cofounder and chief executive officer of VeonGen Therapeutics.
